Real-world study confirms long-term performance of decisiondx®-um for metastatic risk stratification in uveal melanoma and utility of prame biomarker for refining risk when considered with the decisiondx-um class result

Friendswood, texas, may 09, 2025 (globe newswire) -- castle biosciences, inc. (nasdaq: cstl), a company improving health through innovative tests that guide patient care, today announced new data from the first independent validation of the recently published collaborative ocular oncology group study no. 2 (coog2.1) by harbour et al.1 the data, from a real-world cohort of 1,297 patients with uveal melanoma (um), was presented at the association for research in vision and ophthalmology (arvo) 2025 annual meeting in salt lake city.
CSTL Ratings Summary
CSTL Quant Ranking